Vulvovaginal Disease

Learn about the symptoms of vulvovaginal atrophy and their frequency and impact in postmenopausal women, leading to extreme discomfort in some cases.

Learn about the clinical characteristics and varied treatment modalities for vulvovaginal pediatric hemangiomas, highlighting the importance of personalized care according to patient needs and clinician expertise, as revealed in a comprehensive review.

A new study revealed that hybrid vaginal ovules, incorporating curcumin and miconazole nitrate, offer effective relief against Candida albicans, potentially revolutionizing treatment for vulvovaginal candidiasis with reduced dosing frequency and adverse effects.

Delve into the complex interplay between genital infections, antibiotic treatments, and the heightened risk of preterm birth, underscored by recent research findings in Antibiotics.

Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.

A recent study revealed the efficacy of tetrazole oteseconazole against fluconazole-resistant Candida biofilms, offering hope for recurrent candidiasis patients seeking alternative therapies.

Discover how metabolomics sheds light on potential biomarkers for early detection and treatment of Candida albicans-induced vulvovaginal candidiasis, offering crucial insights into the pathogenesis of this prevalent inflammatory condition.

Misunderstandings surrounding bacterial vaginosis can delay treatment, but advancements such as XACIATO offer effective solutions, emphasizing the importance of open communication and continued research for comprehensive women's health care.

Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.

A phase 3 trial demonstrated that oteseconazole (VIVJOA; Mycovia Pharmaceuticals) capsules exhibit improved therapeutic and mycological cure rates to fluconazole for treating severe vulvovaginal candidiasis.

Explore the relationship between bacterial vaginosis and vulvovaginal candidiasis as revealed by a recent study, uncovering mixed interactions, antibiotic implications, and the potential role of vaginal microbiota in shaping this complex association.

In a recent study, vaginal laxity symptoms were significantly improved in patients receiving electroporation therapy vs placebo.

A recent review evaluated the potential of in vivo and in vitro methods for treating vulvovaginal candidiasis.

In a recent study, nanostructured lipid carriers loaded with hypericin and dispersed in hydrogels were effective at managing candida albicans.

In a recent study, certain sexually transmitted infections were more common among patients positive for bacterial vaginosis.

In part 2 of this review, more vulvovaginal diseases are examined.

In part 1 of this review, red flags for severe skin disease are discussed.

In a recent study, no severe adverse events were reported in women with vulvovaginal atrophy who were treated with a vaginal tamoxifen capsule.

A multi-targeted rapid sample processing and testing system has shown efficacy for diagnosing vulvovaginal candidiasis by detecting the presence of Candida species in women.

At the 2023 ACOG Annual Clinical & Scientific Meeting, a look at how AI and immunofluorescence scanning microscopy can help in detecting vaginitis and increase the health of the vaginal microbiome.

Three months ago, a healthy 2-year-old girl presented with a mildly pruritic rash with erythematous plaques, some silvery white, in the vulvovaginal area. She had no vaginal discharge or other symptoms. The rash is now more widespread, and new lesions have recently appeared on her lower back and thighs. What's the diagnosis?

The Xpert Xpress Multiplex Vaginal Panel test (Cephid) has shown high agreement for organisms causing vaginitis and vaginosis.

Becton, Dickinson and Company has announced its BD Vaginal Panel received 510(k) clearance from the FDA.

A new study suggests that ospemifene can reduce harmful bacteria and significantly contribute to vaginal health in postmenopausal women.

After observing an increase in the rate of syphilis cases, the Cleveland Clinic Ob/Gyn & Women’s Health Institute has partnered with the Center for Pediatric Infectious Diseases to evaluate the effectiveness of current testing strategies.

New research suggests that adding probiotics to established VVC treatment options may be a path to increased cure rates.

Ibrexafungerp (Brexafemme; Scynexis) is now approved for the treatment of vulvovaginal candidiasis and reduction in the incidence of recurrent vulvovaginal candidiasis (RVVC).

Michael L. Krychman, MD and Jack D. Sobel, MD, talk about the signs and symptoms of vulvovaginal candidiasis as well as its effect on patient quality of life.

Bacterial vaginosis during pregnancy may lead to increased risks for preterm birth, preterm delivery, and spontaneous abortion, according to new research in the Archives of Gynecology and Obstetrics.

Daré Bioscience announced yesterday that it has received a grant from the Bill & Melinda Gates Foundation of $584,986 to support its efforts related to the development of a vaginal thermosetting gel formulation for the delivery of live biotherapeutics that can be reconstituted at the point of care.